IVA

3.1408.99%
JA

Jason A. Campagna

President of Research & Development and Chief Medical Officer

Mr. Jason A. Campagna, M.D, Ph.D., is Member of Scientific Advisory Board of Rectify Pharmaceuticals, Inc. from February 2023. Mr. Campagna has M.D. from University of Miami. Mr. Campagna has Ph.D. from University of Miami. Mr. Campagna has Bachelor's in Cellular Biology, Molecular Pharmacology, Molecular Biology from University of Miami. since February 2023. He serves as President of Research and Development and Chief Medical Officer at Inventiva S.A. since July 2025. He was Chief Medical Officer at Q32 Bio Inc. since 2024 until June 2025. Mr. Campagna previously served as the Chief Medical Officer of Legacy Q32, where he had been employed since March 2021. Campagna had been Independent Director at Plantable Health Inc. since November 26, 2021 until March 31, 2023. He was Chief Medical Officer at Intercept Pharmaceuticals, Inc. since December 2019 until March 5, 2021. Dr. Campagna joined The Medicines Company in January 2010 and serves as VP and Global Medical Lead for the Medicines Company Surgery / Anesthesia / Critical Care Pathway including most recently as Senior Vice President and Health Science Lead of Surgery and Perioperative Care. In this role he develops and oversees the medical and scientific activities of the Pathway products and services in all 17 countries in which MDCO operates. From August 2005-January 2010, Campagna was the Chief Medical Quality Officer at the Cottage Health System in Santa Barbara, CA. In addition to this, he practiced clinical anesthesia and had faculty appointments at UC Santa Barbara (Neuroscience) and Stanford University (Anesthesia and Critical Care). Campagna serves on the Steering Committee of the Wallace H. Coulter Center for Translational Research at the University of Miami Miller School of Medicine. Campagna has leadership experience in the healthcare industry, including his role as Senior Vice President and NASH Program Leader at Intercept since 2016. Campagna served as a Director at Annovation BioPharma, Inc. until July 2016. Campagna also helped to found and serves as a Board member of the Neurosciences Research Institute (NRI) at UCSB. From 2004-2005 Campagna held an Assistant Professorship in Anesthesia and Critical Care at University of Pennsylvania School of Medicine and was a member of the Mahoney Neurosciences Institute. Prior to this, Campagna held faculty appointments at Harvard Medical School and was an attending Anesthesiologist at the Massachusetts General Hospital in Boston. Campagna earned a PhD in Neuroscience and completed his post-doctoral fellowship at the Neuro Plasticity Research Group at MGH and went on to have his own laboratory at both Harvard and UPenn. He was a Fellow at the Kennedy Institute of Ethics at Georgetown University. Campagna also served as Managing Director of Profibrix B.V., Campagna earned his MD as part of a combined MD/PhD program and completed his internship, residency and fellowships all at MGH in Boston. Campagna is an Oral Board Examiner for The American Board of Anesthesia, a Board Member for Annovation Biosciences based in Cambridge, MA and the NRI in Santa Barbara, CA. Campagna received his M.D., Ph.D. and his bachelor’s degree in Cellular and Molecular Pharmacology/Biology from the University of Miami Miller School of Medicine.

Positions